These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15569457)

  • 21. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
    Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
    Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Masson D; Zerrouki S; Jouan F; Collet N; Dubourg C; Lobel B; Denis M; Fergelot P
    Br J Cancer; 2009 Oct; 101(8):1417-24. PubMed ID: 19755989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
    Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
    Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo.
    Akiyama H; Tanaka T; Itakura H; Kanai H; Maeno T; Doi H; Yamazaki M; Takahashi K; Kimura Y; Kishi S; Kurabayashi M
    Invest Ophthalmol Vis Sci; 2004 May; 45(5):1289-96. PubMed ID: 15111579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
    Pal S; Claffey KP; Dvorak HF; Mukhopadhyay D
    J Biol Chem; 1997 Oct; 272(44):27509-12. PubMed ID: 9346879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Frequent somatic mutations of the von Hippel-Lindau tumor suppressor gene in primary sporadic human renal clear cell carcinomas].
    Gong K; Zhang Z; Xin D
    Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(3):142-4. PubMed ID: 11798864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma.
    Yao M; Yoshida M; Kishida T; Nakaigawa N; Baba M; Kobayashi K; Miura T; Moriyama M; Nagashima Y; Nakatani Y; Kubota Y; Kondo K
    J Natl Cancer Inst; 2002 Oct; 94(20):1569-75. PubMed ID: 12381710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
    Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
    J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.
    Schraml P; Struckmann K; Hatz F; Sonnet S; Kully C; Gasser T; Sauter G; Mihatsch MJ; Moch H
    J Pathol; 2002 Feb; 196(2):186-93. PubMed ID: 11793370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.